Dinaciclib
Term · Oncology and biomedicine · MLC-T-ONC-002479
A substance being studied in the treatment of advanced melanoma (a type of skin cancer) and other types of cancer. It blocks cell division and may cause cancer cells to die. It is a type of cyclin-dependent kinase inhibitor. Also called CDK inhibitor SCH 727965.
A pyrazolo[1,5-a]pyrimidine with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9; inhibition of CDK1 and CDK2 may result in cell cycle repression and tumor cell apoptosis.
| Identifier | MLC-T-ONC-002479 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | CDK inhibitor SCH 727965; cyclin-dependent kinase inhibitor SCH 727965 |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-002479",
"term": "Dinaciclib",
"field": "Oncology and biomedicine",
"definitions": [
"A substance being studied in the treatment of advanced melanoma (a type of skin cancer) and other types of cancer. It blocks cell division and may cause cancer cells to die. It is a type of cyclin-dependent kinase inhibitor. Also called CDK inhibitor SCH 727965.",
"A pyrazolo[1,5-a]pyrimidine with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9; inhibition of CDK1 and CDK2 may result in cell cycle repression and tumor cell apoptosis."
],
"synonyms": [
"CDK inhibitor SCH 727965",
"cyclin-dependent kinase inhibitor SCH 727965"
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/dinaciclib/"
}
Record 6,031 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.